Trial Profile
A retrospective study of Avibactam/ceftazidime in the treatment of Carbapenem-Resistant Enterobacteriaceae infections
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 28 Sep 2016
Price :
$35
*
At a glance
- Drugs Avibactam/ceftazidime (Primary)
- Indications Enterobacteriaceae infections; Gram-negative infections
- Focus Therapeutic Use
- 28 Sep 2016 New trial record